menu search

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...

November 3, 2023, 8:05 pm

Actinium pharmaceuticals: the trickle down continues, and i maintain a buy

Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, whi...

November 3, 2023, 6:08 pm

Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)

– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...

November 3, 2023, 12:30 pm

Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific

– ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action – BRYAN, Texas and ...

November 1, 2023, 12:24 pm

Mersana therapeutics to host third quarter 2023 conference call on november 7, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d...

October 31, 2023, 4:30 pm

Context therapeutics reveals ‘encouraging' preclinical data for ctim-76 tumor treatment

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6...

October 31, 2023, 10:12 am

Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t

– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting ...

October 27, 2023, 1:25 pm

Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...

October 25, 2023, 9:05 am

Ambrx: next-generation antibody-drug conjugates, buying the dip after esmo data

Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting...

October 24, 2023, 11:23 am

Roche enters into a definitive agreement to acquire telavant including rights to novel tl1a directed antibody (rvt-3101) for the treatment of inflammatory bowel disease from roivant

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and ...

October 23, 2023, 5:00 am

Xencor: a mid-stage clinical company with falling losses

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li...

October 20, 2023, 11:02 pm

Trending tickers: at&t, merck-daiichi sankyo, klaviyo: trending tickers october 29, 2023

Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japan...

October 20, 2023, 5:44 pm

Sanofi seeing 'unprecedented' demand for rsv therapy

French drugmaker Sanofi said on Friday it was seeing an "unprecedented level" of demand for its antibody...

October 20, 2023, 2:31 pm

Tourmaline bio announces closing of merger with talaris therapeutics and concurrent private placement of $75 million

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroi...

October 19, 2023, 9:37 pm

Daiichi sankyo and merck team up on $22 bln collaboration for sankyo's antibody drug conjugates

Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd ...

October 19, 2023, 7:46 pm

Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference

– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...

October 18, 2023, 8:30 pm

Hookipa pharma announces publication of preclinical data of hepatitis b virus (hbv) therapeutic vaccine developed in collaboration with gilead sciences

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high ...

October 18, 2023, 11:01 am

Eli lilly is buying another european cancer firm mablink bioscience

Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, ...

October 18, 2023, 10:01 am

Comera life sciences presents sqore™ platform technology data at podd: partnerships in drug delivery conference

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generat...

October 16, 2023, 12:00 pm

New rsv protections for infants hit cost, insurance hurdles in u.s. rollout

Pfizer's maternal vaccine, Abrysvo, and Sanofi's monoclonal antibody, Beyfortus, were approved for expe...

October 13, 2023, 12:22 pm


Search within

Pages Search Results: